Athersys Inc. (ATHX) stock rebounded in the after-hours on Friday, to gain 8.90%. No news from the company is responsible for driving the stock up.
During the previous regular session, ATHX stock traded in the red with a loss of 0.25%. The stock closed the session at $0.8724 on January 07. As soon as the after-market session started, the stock rebounded to reach $0.95 at 173.59K shares.
Currently, the company’s 235.24 million outstanding shares trade at a market capitalization of $205.22 million.
What’s happening with ATHX?
ATHX stock has been trading in the red for the past few days. After losing for four days, the stock finally recovered in the after-hours on Friday. Hence, ATHX started trading in the green in Friday’s after-hours session. No news from the company is responsible for the stock’s recent movements, as the latest news date back to November 30.
In the past five days, the stock has decreased by 3.35% and 13.62% last month. Moreover, the stock stands at a loss of 55.49% in the past year.
MUST-ARDS Clinical Trial
The company has been conducting Phase ½ MUST-ARDS clinical trials in acute respiratory distress syndrome (ARDS) patients. The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety and efficacy of MultiStem® (invimestrocel) cell therapy in the patients. Furthermore, the study enrolled patients at 12 intensive care units in the United Kingdom and the United States. According to the study, in the early course of moderate to severe ARDS, the intravenous administration of the therapy was well-tolerated. Further, several efficacy points were also evaluated in the trial. These include mortality liberation from mechanical ventilation, discharge from ICU, and quality of life among survivors over one full year of recovery.
The ATHX’s ARDS program was granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designation by the FDA.
On November 30, the company announced that a report on the ATHX’s MUST-ARDS clinical trial has been published in the Intensive Care Medicine journal. The report in the peer-reviewed journal includes previously disclosed data from the MUST-ARDS clinical trial.
ATHX’s Financial Highlights
The company disclosed its third-quarter 2021 financial results on November 15.
In the third quarter of 2021, the company generated revenues of $4.8 million, against $0.1 million in Q3 of 2020.
ATHX suffered from a net loss of $16.2 million in the third quarter of 2021, against $22.5 million in the year-ago quarter.
